Security News
BioDelivery Sciences Int’l, Inc. v. Alvogen PB Research & Development LLC
UnknownApr 15, 2026(27 days ago)
The article discusses a case filed in 2018 regarding Alvogen's submission to the FDA for approval to market a generic version of Belbuca.
This case was filed in 2018 when Alvogen submitted to the FDA an ANDA for approval to market generic Belbuca, a buprenorphine buccal film used to administer the drug transmucosally.... By: Robins Kaplan LLP
Related News
Instructure reaches 'agreement' with ShinyHunters to stop data leak
Unknown40 minutes ago
Mini Shai-Hulud Worm Compromises TanStack, Mistral AI, Guardrails AI & More Packages
Unknownabout 1 hour ago
CVE-2026-43500 rxrpc: Also unshare DATA/RESPONSE packets when paged frags are present
Unknownabout 2 hours ago